Current role of pharmacologic therapy for patients with paroxysmal supraventricular tachycardia.
Intravenous antiarrhythmic drugs will continue to have an important role in the acute management of SVT. Long-term antiarrhythmic drug therapy is often effective in preventing or reducing frequency and severity of arrhythmic episodes. The cost, adverse effects, and inconvenience of long-term drug therapy will result in the increasing use of curative ablation for most individuals with problematic SVT.
Basta
M
M
Division of Cardiology, University of Western Ontario, London, Canada.
Klein
G J
GJ
Yee
R
R
Krahn
A
A
Lee
J
J
D000241:Adenosine / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001282:Atrial Flutter / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004077:Digoxin / Q000627:therapeutic use; D004562:Electrocardiography; D006801:Humans; D026902:Potassium Channel Blockers; D013015:Sotalol / Q000627:therapeutic use; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy*; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D026902:Potassium Channel Blockers; D004077:Digoxin; D013015:Sotalol; D000241:Adenosine; D000638:Amiodarone